UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

Rhea-AI Summary

UNITY Biotechnology [UBX] reported Q3 2024 financial results, highlighting progress in developing UBX1325 (foselutoclax) for diabetic macular edema (DME). Following FDA interaction, UNITY expects a pivotal study to be a non-inferiority trial comparing UBX1325 to aflibercept. Financial highlights include cash position of $29.0 million as of September 30, 2024, net loss of $6.5 million (down from $14.8 million in Q3 2023), and reduced R&D expenses of $2.8 million (down from $4.6 million). The company expects topline 24-week data in Q1 2025 and 36-week data in Q2 2025.

Positive

• Net loss decreased significantly from $14.8M to $6.5M year-over-year
• Operating expenses reduced with R&D costs down by $1.8M and G&A expenses down by $0.5M
• Cash burn rate improved with $15.0M used in operations vs $29.5M in previous year

Negative

• Cash position declined from $43.2M to $29.0M since December 2023
• Current cash runway only extends into Q3 2025

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.

“As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision loss over time despite treatment, and high treatment burden leading to discontinuation,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We believe that UBX1325 (foselutoclax) with its novel mechanism of action has the potential to improve long-term visual outcomes for DME patients, via a proven and safe intravitreal route of administration. We believe that the readouts from the Phase 2b ASPIRE study comparing UBX1325 to the aflibercept standard of care will provide a definitive dataset to inform the design of a potential pivotal study.”

In the third quarter of 2024, UNITY had a Type C interaction with the U.S. Food and Drug Administration, or FDA, regarding the development of UBX1325 (foselutoclax) for DME. Based on that interaction, UNITY expects that a pivotal study would need to be a non-inferiority trial comparing UBX1325 to an approved anti-VEGF agent such as aflibercept. The endpoint for regulatory approval is expected to be an assessment of best-corrected visual acuity (BCVA), as assessed by the ETDRS scale with a non-inferiority margin of 4 letters.

The webcast presentation from the Company’s Ophthalmology Investor and Analyst Day is available here.

UBX1325 (foselutoclax) is designed as a novel and durable therapeutic option in diabetic macular edema (DME) that acts via a senolytic mechanism of action, with the potential to address shortcomings of the current standard of care, such as high treatment burden and sub-optimal response to treatment.

UNITY expects topline 24-week primary endpoint data in the first quarter of 2025 and 36-week data in the second quarter of 2025. The Phase 2b ASPIRE study in DME is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept. More information about ASPIRE (NCT06011798) can be found here.

Third Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $29.0 million as of September 30, 2024 compared with $43.2 million as of December 31, 2023. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the third quarter of 2025.

Net loss for the three months ended September 30, 2024, was $6.5 million compared to $14.8 million for the three months ended September 30, 2023. Cash used in operations during the first, second and third quarters of 2024 was $15.0 million compared to $29.5 million during the first, second, and third quarters of 2023.

Research and development expenses decreased by $1.8 million, to $2.8 million for three months ended September 30, 2024, from $4.6 million for the three months ended September 30, 2023. The decrease was primarily due to $0.9 million in personnel costs due to our reduced headcount related to our reduction in force, $0.8 million in direct research and development expenses mainly due to the completion of the Phase 2 BEHOLD study of UBX1325 in patients with DME and the Phase 2 ENVISION study of UBX1325 in patients with AMD, and $0.1 million in operating costs due to reduced fixed assets depreciation and reduced office space.

General and administrative expenses decreased by $0.5 million, to $3.8 million for the three months ended September 30, 2024, from $4.3 million for the three months ended September 30, 2023. The decrease was primarily due to decreases of $0.5 million in personnel-related expenses due to reduced headcount and the reduction in bonus and severance amounts paid as compared to 2023 and $0.1 million in operating costs mainly from the continuation of sublease income generated from the East Grand property, partially offset by an increase of $0.1 million in professional fees and accounting service fees.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 4, 2024, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Unity Biotechnology, Inc. Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts)
	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2024				2023				2024				2023
	(Unaudited)								(Unaudited)
Operating expenses:
Research and development	$	2,787			$	4,632			$	9,971			$	16,828
General and administrative		3,815				4,347				11,209				14,560
Impairment of long-lived assets		—				5,602				—				5,602
Total operating expenses		6,602				14,581				21,180				36,990
Loss from operations		(6,602	)			(14,581	)			(21,180	)			(36,990	)
Interest income		396				689				1,424				2,349
Interest expense		—				(566	)			—				(2,451	)
Gain (loss) on warrant liability		(215	)			253				2,407				2,283
Other income (expense), net		(60	)			(577	)			(201	)			(711	)
Net loss		(6,481	)			(14,782	)			(17,550	)			(35,520	)
Other comprehensive gain (loss)
Unrealized gain (loss) on marketable debt securities		74				81				63				196
Comprehensive loss	$	(6,407	)		$	(14,701	)		$	(17,487	)		$	(35,324	)
Net loss per share, basic and diluted	$	(0.38	)		$	(1.01	)		$	(1.04	)		$	(2.46	)
Weighted-average number of shares used in computing net loss per share, basic and diluted		16,849,283				14,598,218				16,816,706				14,446,672

Unity Biotechnology, Inc. Condensed Balance Sheets (In thousands)
	September 30,				December 31,
	2024				2023
	(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	8,898			$	19,803
Short-term marketable securities		20,139				23,398
Prepaid expenses and other current assets		1,226				3,404
Total current assets		30,263				46,605
Property and equipment, net		4,414				5,082
Operating lease right-of-use assets		11,359				12,981
Long-term restricted cash		896				896
Other long-term assets		200				126
Total assets	$	47,132			$	65,690
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,804			$	1,380
Accrued compensation		1,704				1,841
Accrued and other current liabilities		5,276				4,619
Total current liabilities		8,784				7,840
Operating lease liability, net of current portion		20,698				23,539
Warrant liability		3,506				5,913
Total liabilities		32,988				37,292
Commitments and contingencies
Stockholders’ equity:
Common stock		2				2
Additional paid-in capital		516,006				512,773
Accumulated other comprehensive gain		39				(24	)
Accumulated deficit		(501,903	)			(484,353	)
Total stockholders’ equity		14,144				28,398
Total liabilities and stockholders’ equity	$	47,132			$	65,690

Media
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

FAQ

What were UNITY Biotechnology's (UBX) Q3 2024 financial results?

UNITY reported a net loss of $6.5M, with cash position of $29.0M as of September 30, 2024. R&D expenses were $2.8M and G&A expenses were $3.8M.

When will UBX release topline data for UBX1325 in DME treatment?

UNITY expects to release 24-week primary endpoint data in Q1 2025 and 36-week data in Q2 2025.

What is UBX's cash runway based on Q3 2024 results?

UNITY believes its current cash position is sufficient to fund operations into the third quarter of 2025.

How did UBX's operating expenses change in Q3 2024 vs Q3 2023?

Operating expenses decreased with R&D costs reducing from $4.6M to $2.8M and G&A expenses declining from $4.3M to $3.8M.